Vista Investment Management Buys Shares of 1,637 Vertex Pharmaceuticals Incorporated $VRTX

Posted by Brian Himes on Aug 23rd, 2026

Vista Investment Management purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) in the second quarter, HoldingsChannel reports. The firm purchased 1,637 shares of the pharmaceutical company’s stock, valued at approximately $813,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Compass Financial Management LLC acquired a new position in Vertex Pharmaceuticals during the second quarter worth about $49,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $1,119,000. Alta Advisers Ltd acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $492,000. Daiichi Life Insurance Co. Ltd. purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $7,036,000. Finally, Commerce Bank purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $3,990,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Up 1.4%

Shares of Vertex Pharmaceuticals stock opened at $548.05 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $374.17 and a fifty-two week high of $555.32. The business’s fifty day moving average is $492.65 and its two-hundred day moving average is $465.92. The firm has a market cap of $139.10 billion, a PE ratio of 31.90, a P/E/G ratio of 2.27 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 EPS for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The business had revenue of $3.33 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the company posted $4.52 earnings per share. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.86 EPS for the current year.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Duncan Mckechnie sold 1,541 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the sale, the executive vice president owned 11,001 shares in the company, valued at approximately $5,709,519. The trade was a 12.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 4,062 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $450.00, for a total value of $1,827,900.00. Following the sale, the chief marketing officer owned 16,953 shares of the company’s stock, valued at $7,628,850. The trade was a 19.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 10,464 shares of company stock worth $4,959,397. 0.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on VRTX shares. TD Cowen upped their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. UBS Group boosted their price target on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Stifel Nicolaus set a $500.00 price objective on Vertex Pharmaceuticals in a research report on Tuesday, August 4th. Finally, Sanford C. Bernstein raised Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $563.50.

Get Our Latest Analysis on VRTX

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.